FDAs Coordinated Enforcement on GLP-1 Promotion & Compounding: Hims & Hers, Eli Lilly, and Novo Nordisk Receive Warning Letters on the Same Day Notes from a Clinical & Regulatory Perspective On 2025/9/9, the FDA issued Warning Letters to Hims & Hers, Eli Lilly, and Novo Nordisk on the same day
Archived from the original on 2 March 2015
The greatest concern is that while in the short-term the program could provide health benefits to those who need help with weight management, in the long-term those same problems could return if there is a failure to extend the program past its current end date, Beene said
Una longevit sana si raggiunge attraverso la combinazione di strategie complementari: prevenzione, nutrizione e stile di vita, e diagnosi predittiva per identificare fattori di rischio invisibili che predispongono a sviluppo di malattie
doi:10.1016/0006-291X(63)90024-X
Watch for signs of pancreatitis (severe abdominal or back pain, nausea, vomiting), unusual thirst or frequent urination (signs of blood glucose changes), nausea or loss of appetite beyond expected GLP-1 effects, and any infections or delayed wound healing (steroid-related concerns)
